MSD Animal Health Reinforces Its Commitment to Aquaculture Health
BOXMEER, The Netherlands, April 2, 2013 — MSD Animal Health (known as Merck Animal Health in USA and Canada) recently announced that Coldwater Aquaculture Laboratory of Bergen, Norway, a pioneering research and development laboratory that has significantly contributed to the rapid growth of cold water aquaculture for more than a decade, will now be known as MSD Animal Health Innovation AS.
Previously known as Intervet Norbio Bergen AS, the laboratory was acquired along with Intervet/Schering-Plough Animal Health in 2009 and it is the primary research and vaccine development facility for coldwater aquaculture within MSD Animal Health.
The laboratory has a long history of contributions to the aquaculture industry, most notably the innovative NORVAX® line of vaccines that include NORVAX® Minova 6 and NORVAX® Compact PD.
“We are pleased to bring Coldwater Aquaculture Laboratory into the overall structure of MSD Animal Health. Both organizations have enjoyed a long history of innovation, as well as a proven track record for developing science-based health solutions for animal production,” said Luc Grisez, Ph.D., head of aquaculture research and development for MSD Animal Health.
“One of the major strengths of MSD Animal Health is its existing knowledge of health issues and solutions for many animal species. By combining our passion, expertise, resources and vision with Coldwater Aquaculture Laboratories, we extend our global leadership position in advancing animal health and safety.”
For more information about MSD Animal Health and its commitment to aquaculture, go to http://aqua.merck-animal-health.com or contact your local MSD Animal Health representative.
About MSD Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. MSD Animal Health, known as Merck Animal Health in the United States and Canada, is the global animal health business unit of Merck. MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2011 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).